CERT Certara, Inc.
Price Chart
Executive Summary
Certara agreed to sell its regulatory and medical writing business to Veristat for up to $135 million in cash, consisting of $100 million upfront and up to $35 million in earn-outs. The move sharpens focus on its core Model-Informed Drug Development (MIDD) platform and is expected to close in Q2 2026.
Key Financial Metrics
Actionable Insight
The sale enhances Certara's focus on its higher-margin MIDD and clinical intelligence business; monitor updated 2026 guidance post-closing for revised financial outlook and reinvestment plans.
Key Facts
- Certara is selling its regulatory and medical writing business to Veristat
- Total consideration is up to $135 million: $100 million upfront cash and $35 million in contingent earn-outs
- The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025
- Transaction expected to close in Q2 2026, subject to customary conditions
- Proceeds will be used to accelerate investment in Certara's MIDD platform
Financial Impact
Up to $135 million in proceeds, including $35 million contingent on performance; divests a $50 million revenue business
Risk Factors
- Transaction may not close due to customary closing conditions
- Loss of $50 million in annual revenue and associated EBITDA from the divested business
- Execution risk in redeploying proceeds to drive growth in core platform
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CERT) — Batch item 1 | 0001104659-26-046358 |
| Document: tm2612400d1_ex99-1.htm | press-3278796 |
| Document: 0001104659-26-046358-index-headers.html | 0001104659-26-046358 |
| Document: 0001104659-26-046358-index.html | 0001104659-26-046358 |
| Document: 0001104659-26-046358.txt | 0001104659-26-046358 |
| PRESS-RELEASE Data (Synthetic) | 0001104659-26-046358 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $5.04 awaiting T+5 | awaiting T+5 | — | $5.20 (−3.28%) |
|
May 11, 2026
4w ago
|
8-K
| $5.13 $4.56 | ▲ +11.11% | ▲ +11.03% | $5.20 (−1.36%) |
|
May 11, 2026
4w ago
|
Press Release
| $5.13 $4.56 | ▲ +11.11% | ▲ +11.03% | $5.20 (−1.36%) |
|
Apr 22, 2026
7w ago
|
8-K / PRESS-RELEASE
| $6.38 $6.11 | ▼ −4.23% | ▼ −4.29% | $5.20 (−18.50%) |
|
Apr 3, 2026
10w ago
|
DEFA14A
| $5.46 $5.79 | ▲ +6.04% | ▲ +1.91% | $5.20 (−4.76%) |
|
Mar 30, 2026
11w ago
|
Court Ruling
| $5.68 $5.62 | ▼ −1.06% | ▼ −5.36% | $5.20 (−8.45%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $7.24 $6.93 | ▼ −4.28% | ▼ −3.80% | $5.20 (−28.18%) |
|
Feb 26, 2026
15w ago
|
8-K
| $6.80 $7.15 | ▲ +5.15% | ▲ +6.27% | $5.20 (−23.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access